Avastin doesn't blind people, people blind people

Serafin Gonzalez, Philip J. Rosenfeld, Michael W. Stewart, Jennifer Brown, Steven P. Murphy

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


Purpose: To review the appropriate preparation of bevacizumab for intravitreal injection by compounding pharmacies with specific recommendations designed to prevent microbial contamination. Design: Perspective. Methods: A review and discussion of compounding issues with supporting literature, clinical experience, illustrations, and expert opinion. Results: Closer examination of the events surrounding the recent clusters of infectious endophthalmitis cases occurring after the intravitreal injection of bevacizumab suggest that the vision loss is not the result of the drug or the injection technique, but rather of the compounding procedures used to prepare the syringes containing the bevacizumab. Noncompliance with recognized standards and poor aseptic technique are the most likely causes of these outbreaks. The key to preventing these catastrophic occurrences depends on the implementation of and strict adherence to United States Pharmacopoeia Chapter 797 requirements. Conclusions: Recommendations arising from a root cause analysis of infectious endophthalmitis outbreaks should focus on the procedures used by pharmacies to compound bevacizumab. Microbial contamination of bevacizumab-containing syringes prepared from the same vial of drug can be avoided by using a single vial of bevacizumab for each eye or by following strict adherence to United States Pharmacopoeia Chapter 797 requirements when compounding a single vial of bevacizumab into multiple syringes.

Original languageEnglish (US)
Pages (from-to)196-203.e1
JournalAmerican journal of ophthalmology
Issue number2
StatePublished - Feb 2012

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Avastin doesn't blind people, people blind people'. Together they form a unique fingerprint.

Cite this